louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03784092: Effect Mobility During Induction of Labor on Time to Delivery. A Randomized Controlled Trial
Official title: The Effect of Enhanced Mobility, Controlled Via Electronic Pedometers, During Induction of Labor by Extra Amniotic Balloon on Time to Delivery. A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Labor Onset and Length Abnormalities
Lead sponsor: Wolfson Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-12-21
Enrollment: 224
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: this is a andomized controlled trial the evaluates the effect of enhanced mobility, controlled via electronic pedometers, during induction of labor by extra amniotic balloon on time to delivery.


Eligibility criteria: Inclusion Criteria:

* pregnant women
* low risk pregnancies
* singlelton
* vertex position
* undergoing labor induction with extra amniotic catheter
* no contraindication for enhanced mobility

Exclusion Criteria:

* medical recommendation for limited mobility
* status post cesarean delivery
* twin pregnancy
* premature rupture of membranes
* severe preeclampsia
* maternal comorbidity

Primary outcomes:
measure: time to delivery
timeFrame: labor ( catheter placement till delivery completion)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05962892: A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma
Official title: A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Papillary Thyroid Carcinoma
Thermal Ablation
Keywords: Papillary Thyroid Carcinoma
cohort
Thermal Ablation
Recurrence
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2023-07-27
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with pathologically proven PTC underwent ultrasound-guided percutaneous thermal ablation.

Brief summary: A prospective cohort of papillary thyroid carcinoma(PTC), patients who received thermal ablation in our hospital since February 2023 was established as the study object. Preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. The influencing factors of PTC recurrence were analyzed.


Eligibility criteria: Inclusion Criteria:

①≥18 years old; ② Obtain informed consent; ③ Ultrasonography showed that malignant nodules were single, the maximum diameter of nodules was ≤1cm and the distance from the capsule was ≥2mm. ④ no lymph node metastasis or other extra-glandular metastasis in the neck; ⑤ PTC was confirmed by fine needle puncture pathology; ⑥ Patients who do not meet Article 3, who still strongly request thermal ablation while fully informing the patient of the risk of recurrence, and who have been clinically assessed to be technically capable of thermal ablation Exclusion Criteria:① Pregnant or lactating patients; ② Patients with other malignant tumors and not suitable for ablation by clinical evaluation; ③ Patients who cannot tolerate surgery; ④ Patients with cognitive impairment and other conditions who cannot accurately fill in thyroid-related questionnaires.

Primary outcomes:
measure: the recurrence of PTC
timeFrame: 1 to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital
Study officials:
References:
Clinical trial NCT02731092: Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants
Official title: Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Very Low Birth Weight Infants
Keywords: lactoferrin
very low birth weight infants
preterm infants
Lead sponsor: University of Virginia
Sponsor class: OTHER
Collaborators: name: The Gerber Foundation
First posted: 2016-04-07
Enrollment: 30
Sex: ALL
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and tolerability of three different lactoferrin doses in preterm infants

Detailed description: Aim1: To evaluate the safety and tolerability of three different lactoferrin doses in preterm infants

1. Lactoferrin related adverse events and serious adverse events
2. Number of infants reaching full feeds while receiving lactoferrin (120 ml/kg/day)
3. Episodes of not receiving enteral feedings for \> 24 hours once feeding is initiated

Aim 2: To evaluate lactoferrin absorption and excretion.

1. Examine lactoferrin levels in saliva, urine, plasma and stool
2. Examine lactoferrin levels in maternal and human donor milk.

Aim 3: To evaluate the effect of lactoferrin on the intestinal microbiome structure.

Eligibility criteria: Inclusion Criteria:

* \< 15 days of age and receiving enteral feedings
* \< 1500 grams birth weight
* \<37 weeks gestation

Exclusion Criteria:

* Congenital bowel obstruction ( esophageal, duodenal, small bowel or anal atresias, Hirschsprung disease, malrotation)
* Known necrotizing enterocolitis or bowel perforation

Primary outcomes:
measure: Definitely related study solution serious adverse event
timeFrame: 30 days while receiving study solution
Secondary outcomes:
measure: Number of infants reaching 120 ml/kg of enteral feeds
timeFrame: 30 days while receiving study solution
measure: Number of days not receiving any feedings after lactoferrin administration
timeFrame: 30 days while receiving study solution
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia Neonatal Intensive Care Unit
state: Virginia
city: Charlottesville
country: United States
facility: University of Virginia HealthSystem
state: Virginia
Study officials:
affiliation: University of Virginia School of Medicine
name: David A Kaufman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00433992: Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications
Official title: Effects of Thymidine Sparing Regimens on Mitochondrial Metabolism and Adipocyte Apoptosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Keywords: Mitochondria
Fat apoptosis
Lipoatrophy
Lipodystrophy
Thymidine
Treatment experienced
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
First posted: 2007-02-12
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HIV-infected patients who are enrolled in ACTG A5202, starting their first nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen

Brief summary: The purpose of this study is to observe the effects of certain anti-HIV medications on mitochondrial activity and fat cell death. This study will enroll participants from another study, ACTG A5202, who are on treatment regimens that do not include zidovudine, stavudine, or other thymidine-containing anti-HIV medications.

Detailed description: The main objective of this study is to observe the effects of anti-HIV medication lacking thymidine on mitochondrial metabolism and adipocyte apoptosis (fat cell death). Changes in mitochondrial metabolism and increases in adipocyte apoptosis are associated with lipoatrophy. Lipoatrophy is a common condition characterized by loss of subcutaneous fat and can be caused by many anti-HIV medications. This study will examine the metabolic consequences of the use of thymidine analogue-sparing treatment regimens.

This study will evaluate HIV infected patients who are enrolled in ACTG A5202, starting their first nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen. This regimen will include either tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC), which are thymidine-sparing regimens. The changes in mitochondrial activity and fat cell death will be compared between participants taking thymidine-sparing regimens (TDF/FTC or ABC/3TC) and thymidine-containing regimens.

This study will last for 96 weeks, with two study visits occurring at entry and another visit at Week 96. During each visit, a dual energy x-ray absorptiometry (DEXA) scan and blood collection will occur, and a fat biopsy will be performed in the lower abdomen under local anesthetic.

Eligibility criteria: Inclusion Criteria:

* HIV-infected
* Enrolling in ACTG A5202 and its metabolic substudy ACTG A5224

Exclusion Criteria:

* Bleeding problems
* Cannot undergo fat biopsies
* Require aspirin anytime in the 7-day period prior to each biopsy

Primary outcomes:
measure: Change in Mitochondrial Activity
timeFrame: Entry, Week 96
Secondary outcomes:
measure: Change in Fat Apoptosis
timeFrame: Entry, Week 48
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Case School of Medicine
state: Ohio
Study officials:
affiliation: Case School of Medicine
name: Grace McComsey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00679692: Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
Official title: Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis
Liver Cirrhosis
Hepatocellular Carcinoma
Keywords: GH,IGF-1, IGFBP-3
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2008-05-19
Enrollment: 210
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute hepatitis liver cirrhosis hepatocellular carcinoma

Brief summary: BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and human growth hormone (HGH) in the progression of chronic liver disease remain to be elucidated and investigated.

METHODS The subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. Blood was drawn by venipuncture into Venoject tubes. To find the possible correlations between liver damage and IGFs, serum IGF-1, GH, IGFBP-3 concentration and related biochemical parameters were measured. We used immunoradiometric assay to determine the levels of IGF-1, HGH and IGFBP-3 in serum.

Detailed description: healthy controls:one blood sample (7.5 cc) hepatitis: three blood samples, at admission, at 3rd and 7-10th day of admission liver cirrhosis: two blood samples, at 1-2 years interval (7.5 cc/each session) hepatocellular carcinoma: three blood samples, before, 1 day after and at the 7th day of transcatheter arterial chembolizatiom

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Hepatocellular carcinoma
* Must be primary Hepatocellular carcinoma and untreament

Exclusion Criteria:

* treatment Hepatocellular carcinoma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road
Study officials:
affiliation: Kaohsiung Medical University
name: chiou m Lin, Ms
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02023892: Single Dose of Atorvastatin and Circulating Endothelial Microparticles
Official title: The Effect of Single Dose of Atorvastatin on Change of Circulating Endothelial Microparticles
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Endothelium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2013-12-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Healthy subjects take single dose of 80mg atorvastatin, then measured their circulating endothelial microparticles and flow-mediated vasodilation in the brachial artery by ultrasound at different time points.


Eligibility criteria: Inclusion Criteria:

* healthy youth

Exclusion Criteria:

* acute pathologies
* familial history of cardiovascular disease
* smoking or drinking alcohol

Primary outcomes:
measure: change of circulating endothelial microparticles
timeFrame: from 1h to 24h after taking atorvastatin
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01427192: Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension
Official title: Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension (CSRPH)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pulmonary Hypertension
Breathing-Related Sleep Disorder
Keywords: Breathing-Related Sleep Disorder
Pulmonary Hypertension
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2011-09-01
Enrollment: 23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to study the differential short-term effect of nocturnal oxygen, acetazolamide tablets and nocturnal non-invasive positive pressure ventilation on symptoms, exercise capacity and nocturnal breathing disturbances in subjects with pulmonary hypertension and sleep related breathing disorders

* Trial with medicinal product


Eligibility criteria: Inclusion criteria:

* percapillary pulmonary hypertension diagnosed by right heart catheterisation -- stable therapy and clinical condition for at least 4 weeks
* sleep disordered breathing with apnea/hypopnea index \> 10 events/h and/or median nocturnal oxygen saturation \<90%

Exclusion criteria:

* Pregnancy
* severe daytime hypoxemia (PaO2 \< 7.2 kPA)
* patients with predominantly obstructive sleep apnea.

Primary outcomes:
measure: exercise capacity
timeFrame: 1 week
measure: Quality of Life
timeFrame: 1 week
Secondary outcomes:
measure: sleep related breathing disorders
timeFrame: 1 week
measure: hemodynamics measured by echocardiography
timeFrame: 1 week
measure: venous blood analysis
timeFrame: 1 week
measure: Nocturnal oxygen desaturation
timeFrame: 1 week
measure: arterial blood analysis
timeFrame: 1 week
measure: Vigilance
timeFrame: 1 week
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Respiratory Clinic, University Hospital of Zurich
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
citation: Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest. 2008 Jun;133(6):1375-1380. doi: 10.1378/chest.07-3035. Epub 2008 Mar 13.
citation: Schumacher DS, Muller-Mottet S, Hasler ED, Hildenbrand FF, Keusch S, Speich R, Bloch KE, Ulrich S. Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing. Chest. 2014 Nov;146(5):1226-1236. doi: 10.1378/chest.14-0495.
citation: Ulrich S, Keusch S, Hildenbrand FF, Lo Cascio C, Huber LC, Tanner FC, Speich R, Bloch KE. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. Eur Heart J. 2015 Mar 7;36(10):615-23. doi: 10.1093/eurheartj/eht540. Epub 2013 Dec 23.
Clinical trial NCT03639792: Escorting Octogenarian for Gastric Cancer Surgery
Official title: Escorting Octogenarian for Gastric Cancer Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastric Cancer
Keywords: gastric cancer
postoperative complication
octogenarian
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2018-08-21
Enrollment: 61
Sex: ALL
Minimum age (years): 80
Maximum age (years): 90
Standard ages: OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A cohort of gastric cancer patients who underwent surgery during two consecutive years in a Chinese hospital.

Brief summary: An objective analysis of postoperative complications is vital to escort octogenarian for gastric cancer surgery. Investigator carefully collected clinical data prospectively to pave way for standard management in high risk patients.

Detailed description: An objective analysis of postoperative complications is vital to escort octogenarian for gastric cancer surgery. Investigator carefully collected clinical data prospectively to pave way for standard management in high risk patients. Detailed data on surgical indication, assessment for proposed surgery and perioperative management are analyzed for future guidelines in senile.

Eligibility criteria: Inclusion Criteria:

- Pathologically confirmed gastric cancer patients Clinically fit for gastric cancer surgery

Exclusion Criteria:

- Non gastric cancer patients Clinically unfit for gastric cancer surgery

Primary outcomes:
measure: Postoperative Morbidity and mortality
timeFrame: One month after hospital discharge
Secondary outcomes:
measure: Overall survival
timeFrame: upto two years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital Shanghai Jiaotong University School of Medicine
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Birendra K Sah, Ph D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05544292: Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors
Official title: Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors - a Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Immune-related Adverse Event
Keywords: arthritis
check point inhibitor
irAE
Lead sponsor: Diakonhjemmet Hospital
Sponsor class: OTHER
Collaborators: name: Oslo University Hospital
name: Alesund Hospital
name: University Hospital of North Norway
name: Hospital of Southern Norway Trust
name: Helse Nord-Trøndelag HF
First posted: 2022-09-16
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients referred with symptoms of a rheumatic condition after cancer treatment with a check point inhibitor

Brief summary: RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.


Eligibility criteria: Inclusion Criteria:

* De novo symptoms of rheumatic disease or a flare of established rheumatic disease after \>/= 1 dose of treatment with an immune check point inhibitor
* Adult patients (\> 18 years)
* Subject capable of understanding and signing an informed consent form

Exclusion Criteria:

• Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult

Primary outcomes:
measure: Swollen joint count
timeFrame: 1 year follow-up
Secondary outcomes:
measure: C reactive protein
timeFrame: 1 year
measure: Proportion of pateints with arthritis after one year
timeFrame: 1 year
Other outcomes:
Locations:
city: Kristiansand
country: Norway
facility: Hospital of Southern Norway Trust
city: Levanger
country: Norway
facility: Levanger Hospital
city: Oslo
country: Norway
facility: Diakonhjemmet Hospital
city: Tromsø
country: Norway
facility: University Hospital of North Norway
city: Ålesund
country: Norway
facility: Ålesund Hospital
Study officials:
affiliation: Diakonhjemmet Hospital
name: Marte S Heiberg, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05476692: Clinical Outcome of Surgical Treatment for Osteochondral Lesions of the Talus
Official title: Clinical Outcome of Surgical Treatment for Osteochondral Lesions of the Talus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteochondral Lesion of Talus
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-07-27
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 60
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: the study is a descriptive case series study. The sample will be included from the admitted 40 patients during 12 months from the start of the study

Brief summary: Assess clinical and radiological outcome of the various surgical techniques for treatment of osteochondral lesions of the talus

Detailed description: Osteochondritis dissecans (OCD) of the talus is a subchondral bone pathology that presents as an osteochondral lesion of the talar dome with consequent articular cartilage abnormalities. Osteochondral lesions of the talus (OLT) are frequent after acute ankle trauma. The natural history of the OLT remains unclear due to paucity of longitudinal follow-up studies. Various treatment strategies have been described for OLT, including conservative treatment and operative treatment However, the current literature does not allow firm evidence-based recommendations concerning the treatment to be established ; Microfracture is the most common reparative surgery for osteochondral lesions of the talus (OLTs). While shown to be effective in short- to midterm outcomes, the fibrocartilage that microfracture produces is both biomechanically and biologically inferior to that of native hyaline cartilage and is susceptible to possible deterioration over time following repair . Arthroscopic debridement (AD) for the osteochondral lesions of the talar dome (OLT) was widely documented in the nineties with satisfactory results. However, in modern treatment algorithms, its role is not described. A frequently used instrument for assessing outcome after ankle and hindfoot injuries is the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score .

Eligibility criteria: Inclusion Criteria:

* Age from 15 to 60 years old.
* Traumatic and degenerative etiology.
* without ankle deformity.
* No inflammatory arthritis.
* Absent or corrected ligamentous instability

Exclusion Criteria:

* Older than 60 years old and younger than 15 years old.
* Charcot ankle.
* Vascular injury.

Primary outcomes:
measure: clinical outcome of the various surgical techniques for treatment of osteochondral lesions of the talus
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: